Bright Minds Biosciences Inc Total Liabilities
Bright Minds Biosciences Inc total liabilities. Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has total liabilities worth $2.55 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bright Minds Biosciences Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bright Minds Biosciences Inc (2019–2025)
Total liabilities of Bright Minds Biosciences Inc from 2019 to 2025. This chart illustrates how Bright Minds Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Bright Minds Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Bright Minds Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
USA | $161.76 Million |
|
UTKARSH SMALL FINANCE BANK ORD (BSE)
NSE:UTKARSHBNK
|
India | Rs256.73 Billion |
|
Best SA
WAR:BST
|
Poland | zł1.71 Billion |
|
AC IMMUNE SA SF-02
F:IMR
|
Germany | €115.23 Million |
|
Heng Sheng Holding Group Limited
KQ:900270
|
Korea | ₩52.60 Billion |
|
Silicon Valley Acquisition Corp. Class A Ordinary Shares
NASDAQ:SVAQ
|
USA | $8.95 Million |
|
Chicago Atlantic Real Estate Finance Inc
NASDAQ:REFI
|
USA | $160.05 Million |
|
Comstock Mining Inc
NYSE MKT:LODE
|
USA | $58.38 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Bright Minds Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bright Minds Biosciences Inc balance sheet assets.
Liquidity & Leverage Metrics
Bright Minds Biosciences Inc Total Liabilities Ratios Explained
Bright Minds Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 121.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bright Minds Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Bright Minds Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $2.38 Million | +318.23% |
| 2024-09-30 | $568.26K | +102.33% |
| 2023-09-30 | $280.86K | -81.82% |
| 2022-09-30 | $1.54 Million | +141.86% |
| 2021-09-30 | $638.57K | +323.11% |
| 2020-09-30 | $150.92K | +311.14% |
| 2019-09-30 | $36.71K | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more